Gerresheimer's Lasix® ONYU Approved by FDA

Gerresheimer AG announced that the FDA has approved SQ Innovation's Lasix® ONYU, a pioneering combination of furosemide and an on-body device. This innovation is designed, developed, and manufactured by Gerresheimer, enabling at-home subcutaneous infusion of furosemide for selected patients. This development marks a significant step in treating edema in congestive heart failure.

The device, based on Gerresheimer's infusor platform, uses micropump technology for precise drug administration. The user-friendly infusor features a two-component design, aligning with EcoDesign principles to reduce waste and lower costs. This also allows the infusion to occur at home, potentially reducing hospital stays.

Lasix ONYU will be available by the end of 2025, as Gerresheimer handles its production, highlighting the company's strength in innovation and its commitment to addressing healthcare trends.